10x Genomics reported a loss for the third quarter, missing both earnings and revenue expectations. The company cited sales restructuring and cautious customer spending as factors. While the stock initially declined, it rebounded on Wednesday, likely due to the reduced revenue guidance indicating a potential bottoming out of the company’s performance. Analyst ratings remain mixed, with some maintaining their buy recommendations despite lowering price targets.
